RPM and Medicare in 2026: A growing body of data about patient health and outcomes

Growing evidence supports the clinical and financial benefits of proactive remote patient monitoring (RPM), particularly across key moments in the patient journey such as post-discharge or after a new diagnosis. As RPM programs expand, future analysis will likely focus on identifying which patient subgroups benefit most, enabling more targeted and effective interventions, said Lucienne Marie Ide, MD, PhD, founder and CEO of Rimidi, a company that works with RPM, and the author of an analysis of the 2026 schedule.

Medical Economics: Remote patient monitoring logs details about patient health benefits and outcomes. What do the data show?

Lucienne Marie Ide, MD, PhD: We are amassing a body of evidence to support the benefit of this kind of proactive management. Within this sort of general concept of remote monitoring, right, there are all sorts of different use cases, and by that, I mean within the patient journey, so immediately post discharge, after starting a new medication, after getting a new diagnosis. And I think that level of granular data is what's going to be very interesting to look at over the coming years, as these programs grow and scale, and we can start to sort of sub-segment patient populations and say, where are these programs really most beneficial, both clinically and financially? So that's what I anticipate we'll see down the road, because I think we've seen the general impact on improvement in blood pressure, improvement in glycemic control, reduction in readmission for heart failure. Now the question is, are there certain patients who are even more likely to benefit than others, and how do we target them with specific interventions?